

**ASX & MEDIA RELEASE
2 OCTOBER, 2012**



**MEI PHARMA ISSUED EUROPEAN PATENT FOR LEAD MITOCHONDRIAL
INHIBITOR DRUG CANDIDATE ME-344**

Novogen Limited's subsidiary, Marshall Edwards, Inc., (NASDAQ: MEIP), has made the following announcement:

San Diego – 2 October, 2012 – MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that the European Patent Office has issued a new patent, European Patent No. 1 794 141 B1, covering the pharmaceutical composition of the company's lead mitochondrial inhibitor candidate, ME-344, and its use in treating cancer. The patent is expected to provide protection until September, 2025.

"This key European patent further reinforces the intellectual property protection surrounding our portfolio of oncology drug candidates," said Daniel P Gold, PhD, President and Chief Executive Officer of MEI Pharma. "While we continue to execute our Phase I clinical trial for ME-344 and prepare for our upcoming Phase II trials, we believe a strong patent estate will help to provide a clear development path forward and enhance our partnering efforts in the US and abroad."

MEI Pharma owns exclusive worldwide rights to all of its drug candidates, including ME-143, ME-344 and Pracinostat. The company's intellectual property portfolio now includes 18 issued US patents and more than 150 issued foreign patents.

About MEI Pharma

MEI Pharma, Inc. is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The company's clinical development pipeline includes two isoflavone-based drug candidates derived from its proprietary technology platform, ME-143 and ME-344, and a potential best-in-class, oral histone deacetylase (HDAC) inhibitor, Pracinostat. Results from a Phase I dose-escalation trial of lead NADH oxidase inhibitor ME-143 in heavily treated patients with solid refractory tumours were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of lead mitochondrial inhibitor ME-344 in patients with solid refractory tumours is ongoing. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic disorders such as acute myeloid leukemia, myelodysplastic syndrome and myelofibrosis. For more information, go to www.meipharma.com.

About Novogen

Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, MEI Pharma, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR	:	NOVOGEN LIMITED
LISTINGS	:	ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER	:	PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE
INFORMATION :		COMMUNICATIONS, MARSHALL EDWARDS, INC.
		TEL +1 858-792-3729
		http://www.marshalledwardsinc.com
ISSUED BY	:	WESTBROOK COMMUNICATIONS
CONTACT	:	IAN WESTBROOK TEL (02) 9231 0922